Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122610 · ClinicalTrials.gov registry record · Phase 1
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
A Phase 1 study of Neuroendocrine Tumors and Somatostatin Receptor-positive Neuroendocrine Tumor, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06122610: Recruiting Phase 1 study of Neuroendocrine Tumors and Somatostatin Receptor-positive Neuroendocrine Tumor, sponsored by University of Wisconsin, Madison.
NCT06122610 is a Phase 1 study of Neuroendocrine Tumors and Somatostatin Receptor-positive Neuroendocrine Tumor that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 10 participants, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06122610, a Phase 1 study of Neuroendocrine Tumors and Somatostatin Receptor-positive Neuroendocrine Tumor, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
Primary Outcome
Absorbed doses to organs will be estimated using radiation dosimetry methods based on both multi-timepoint PET and multi-timepoint SPECT imaging. Mean dose estimates in units of Gy to the index tumor(s) and dose limiting organs (kidneys and bone marrow) will be compared between PET-based dosimetry and SPECT-based dosimetry. Using SPECT-based dosimetry as the gold standard truth, Bland-Altman analysis will be performed for each organ/tumor to compare PET-based dose estimates to SPECT-based estima
Conditions Studied
Interventions
- DEVICE Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
- DEVICE Photon Emission Tomography / CT (PET/CT)
- DRUG 64Cu-Dotatate
- DRUG 177Lu-Dotatate
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT06122610 shows while recruiting
NCT06122610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 4 interventions - of which Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) is the first listed.
NCT06122610 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06122610 about?
NCT06122610 is a clinical study titled "Using Novel Imaging to More Safely Treat Neuroendocrine Tumors". The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
What is the current status of trial NCT06122610?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-03-07. Estimated completion is 2026-06.
What conditions does trial NCT06122610 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor.
What interventions are being tested in trial NCT06122610?
The interventions under investigation include: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) (DEVICE), Photon Emission Tomography / CT (PET/CT) (DEVICE), 64Cu-Dotatate (DRUG), 177Lu-Dotatate (DRUG).
Who is sponsoring clinical trial NCT06122610?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122610 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06122610's enrollment target sits among peer trials
10 50th of 52 higher than 2 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
RECRUITING · Phase 1
-
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI